CorMedix
Bridgewater · Founded 2006
About CorMedix
CorMedix Inc. is a specialty pharmaceutical company that develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Specifically, our goal is to treat human disease by reducing commonly associated renal, cardiovascular, metabolic and infectious complications. Our therapeutic candidates may be small molecules, biologics, chemical entities, devices and/or diagnostics (molecular/lab tests) that enable targeted therapy in these areas. CorMedix has received CE Mark approval for Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients. Our goal is to provide risk mitigation solutions for central venous catheters (CVCs) in a variety of important indications.
Company Facts
- Founded: 2006
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $96.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: nysemkt:CRMD
- Website: cormedix.com
- Phone: 908-517-9500
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/cormedix-16310 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.